Press Releases

Date Title and Summary View
Aug 08, 2022
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2/3 study in prostate cancer by year-end Initiates cost-saving measures through corporate restructuring with focus on key clinical programs, extending cash runway into 2024 with
Jul 25, 2022
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Jul 08, 2022
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
ROCKVILLE, MD , July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of July 7, 2022 , the Company closed the
Jun 08, 2022
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
May 23, 2022
MacroGenics Announces Appointment of William Heiden to Board of Directors
ROCKVILLE, MD , May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors,
May 17, 2022
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD , May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
May 03, 2022
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies Conference call scheduled for today at 4:30 p.m. ET.
Apr 25, 2022
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD , April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Mar 03, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Feb 28, 2022
MacroGenics Announces Executive Promotion
ROCKVILLE, MD , Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer,
Feb 24, 2022
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumab Presented encouraging preclinical combinatorial anti-tumor
Feb 14, 2022
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Feb 03, 2022
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Nov 03, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Nov 02, 2021
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug substance Discontinuing enrollment of Cohort A of
Oct 26, 2021
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Sep 16, 2021
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A 78% of patients had tumor shrinkage at first scan Median duration of response was 10.3 months as of data cutoff Margetuximab
Sep 16, 2021
MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed) Non-small cell
Sep 12, 2021
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD , Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple
Sep 07, 2021
MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS
Sep 02, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD , Sept. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in
Aug 05, 2021
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the
Jul 29, 2021
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results
Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a biopharmaceutical company
Jul 22, 2021
MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD , July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial
Jun 16, 2021
MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors Zai Lab provides rights to MacroGenics